1 / 20

Traditional EPI: BCG, DTP, DT/Td, HepB, TT, Measles, MMR, MR, tender overview

Traditional EPI: BCG, DTP, DT/Td, HepB, TT, Measles, MMR, MR, tender overview. Pre-tender meeting UNICEF Supply Division, 11 December 2008 Katinka Rosenbom, Yalda Momeni. Assessment of traditional EPI vaccine procurement Principles & Objectives. Objective 1. Continued, sustainable supply

saul
Download Presentation

Traditional EPI: BCG, DTP, DT/Td, HepB, TT, Measles, MMR, MR, tender overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Traditional EPI:BCG, DTP, DT/Td, HepB, TT, Measles, MMR, MR, tender overview Pre-tender meetingUNICEF Supply Division, 11 December 2008Katinka Rosenbom, Yalda Momeni

  2. Assessment of traditional EPI vaccine procurement Principles & Objectives • Objective • 1. Continued, sustainable supply • 2. Quality vaccines (WHO pre-qualification) • 3. Multiple manufacturers per vaccine • 4. Affordable prices • Assessment (2001-2007) • 1. No major interruptions / sufficient to meet demand (with adjustments for some campaigns) • 2. No major vaccine-caused AEFI • 3. Achieved overall, except measles • 4. Mixed, related to (3)

  3. BCG – Procurement Overview – Historical • Relatively stable demand, fluctuations occurring due to countries exiting or entering UNICEF Procurement • 2008 reduced quantities due to Pakistan self procurement

  4. Upcoming Tender Period BCG – Procurement Overview – Forecast • Forecast remain stable during the next tender period • Quantities based on demand from multiple countries

  5. Summary of BCG tender quantities

  6. DTP

  7. Managing DTP based product transitions • Demand • The successful introduction of combination vaccines, needs careful transition management, and is impacting our forecast accuracy • The tender aims at transparency on uncertainty by identifying known uncertain quantities due to product change (switchers) • Funding • When funding availability is a major determinant we share scenarios outlining the different demand profiles

  8. Increasing quantities for all DTP-containing vaccines since 2001 • Trend in shift to DTP-combination vaccines, primarily DTP-HepB/Hib, expected to continue in the next tender period

  9. DTP – Procurement Overview – Historical • Steady decrease as countries shift to combination vaccines

  10. Upcoming Tender Period DTP – Procurement Overview – Forecast • Steady decrease in demand as countries shift to combination vaccines

  11. Upcoming Tender Period DTP – Procurement Overview – Forecast, including potential switchers • Additional countries likely to introduce combination vaccines during the tender period • Potential switchers, notably Nigeria, Myanmar (GAVI) and Philippines (non-GAVI)

  12. Summary of DTP tender quantities

  13. Summary of DT and Td tender quantities • DT demand consists of small quantities from a number of countries. • 75% of the Td demand is from one country only (Haiti).

  14. HepB vaccines

  15. On an aggregate level, there has been a steady increase in all HepB containing vaccines since 2001 • GAVI support began in 2001 as well as introduction in non-GAVI supported countries • Shifts between products, with trend towards combination vaccines • HepB no longer supported by GAVI as a monovalent vaccine, no new countries to introduce

  16. HepB – Procurement Overview – Historical • Remaining quantities dependant on a few large countries • Demand decreasing as countries introduce combination vaccines

  17. Upcoming Tender Period HepB – Procurement Overview – Forecast • Remaining quantities dependant on a few large countries • Demand decreasing as countries introduce combination vaccines

  18. Upcoming Tender Period HepB – Procurement Overview – Forecast, including potential switchers • Further decrease in demand expected as additional countries introduce combination vaccines, potential switchers (Nigeria & Philippines) • Demand continues for HepB1 as countries introduce a birth dose (~2 m doses per year).

  19. Historically, majority of HepB demand has been supported by GAVI, but moving forward demand will be funded by different sources.

  20. Summary of HepB tender quantities

More Related